Source: Annual Congress 2006 - Sarcoidosis

Abstract

Tumor necrosis factor alpha (TNF-a) is proinflammatory cytokine and plays an important role in pathogenesis of sarcoidosis. During last 3 years we use TNF-a inhibitor in the treatment of patients with I and II stages of pulmonary sarcoidosis (PS).
Aim was to analyze the effect TNF-a inhibitor Pentoxifylline (Vasonit - Lannacher Heilmittel, Austria) in patients with I and II stages of PS.
Material and methods. The basic group consisted of 20 patients with I (n=11) and II (n=9) stages of PS and was treated by Pentoxifylline in dose 600 mg every day for 3 months. The control group was formed analogous 17 patients with natural course of PS. The effect of treatment was evaluated by clinical symptoms, chest X-ray and CT, pulmonary function tests (PFTs). Control investigations were executed in 3 months after treatment.
Results. After 3 months we observed clinical improvement in most patients of basic group with frequency 0,85 vs. 0,35 in control group. The improvement of the chest X-ray picture after Pentoxifylline treatment was observed with frequency 0,65 vs. 0,29 in control group. The worsening of chest X-ray picture in basic group was revealed with frequency 0,20 vs. 0,71 in control group. The tendency to improvement of PFTs was observed only in patients of basic group.
Conclusion. The results of investigation demonstrate the need to use Pentoxifylline as an TNF-a inhibitor in patients with I and II stages of PS.

Rating:

Share or cite this content

Citations should be made in the following way:
N. V. Refiskaya, T. A. Stepanenko, P. K. Jablonskiy, O. P. Baranova (St. Petersburg, Russian Federation). The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis. Eur Respir J 2006; 28: Suppl. 50, 3134

Member's Comments

No comment yet.

Related content which might interest you: Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Effects of oxygen supplementation on the secretion of tumour necrosis factor alpha (TNFα) in hypoxaemic COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 209s Year: 2001 Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene Source: Eur Respir J 2002; 19: 912-918 Year: 2002 Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Measurement of tumour necrosis factor converting enzyme (TACE) activity on alveolar macrophages from healthy subjects and subjects with inflammatory lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 417s Year: 2002 Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006 Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial Source: Eur Respir J 2014; 43: 295-298 Year: 2004 Serum leptin and tumor necrosis factor – alpha levels and maximal exercise performance in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Respiratory muscles in disease Year: 2008 Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up Source: International Congress 2016 – Mixed-up imaging of various chest diseases Year: 2016 The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 85s Year: 2007 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Analysis of tumor necrosis factor receptor 1 (TNFR1) polymorphisms in patients with cryptogenic fibrosing alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 411s Year: 2001